Ang, Daniel and Chan, Johan and Ong, Whee Sze and Tan, Hui Shan and Ng, Quan Sing and Yuen, John and Chen, Kenneth and Tay, Kae Jack and Wong, Siew Wei and Saad, Marniza and Nagata, Masayoshi and Horie, Shigeo and Chansriwong, Phichai and Ng, Chi-Fai and Wong, Alvin and Chua, Melvin L. K. and Toh, Chee Keong and Tan, Min-Han and Lim, Tony and Bhagat, Ali Asgar S. and Kanesvaran, Ravindran (2024) Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 8. e2300694. ISSN 2473-4284, DOI https://doi.org/10.1200/PO.23.00694.
Full text not available from this repository.Abstract
PURPOSEAndrogen receptor splice variant 7 (ARV-7) is a resistance mechanism to hormonal therapy in metastatic castrate-resistant prostate cancer (mCRPC). It has been associated with poor outcomes. On progression to castrate resistance, ARV-7 positivity has been identified in global populations at an incidence of 17.8%-28.8%. Here, we characterize the incidence of ARV-7 positivity in Asian patients with mCRPC in a prospective fashion and evaluate its implications on treatment outcomes.METHODSPatients with mCRPC from multiple centers in Southeast and East Asia were enrolled in a prospective manner before initiation of androgen receptor signaling inhibitors or docetaxel. ARV-7 status was evaluated at baseline with three commercially available assays: AdnaTest Prostate Cancer platform, Clearbridge method, and IBN method. Clinical outcomes at progression were assessed. The primary end point of this study was prevalence of ARV-7 positivity; secondary end points were incidence of ARV-7 positivity, prostate specific antigen (PSA) response rate, PSA progression-free survival (PFS), and overall survival (OS).RESULTSA total of 102 patients with a median age of 72 years at enrollment participated. Overall, an incidence of ARV-7 positivity of between 14.3% and 33.7% in Asian patients with mCRPC was demonstrated depending on the assay used. Patients found to have ARV-7 positivity at enrollment had a numerically worse PSA PFS compared with ARV-7 negative patients.CONCLUSIONIn this study, the incidence of ARV-7 positivity in Asian patients with mCRPC was shown to be similar to the global population. Patients with ARV-7 positivity appear to have more aggressive disease with numerically worse PSA PFS and OS. Further prospective studies are needed to fully characterize the relationship that ARV-7 positivity has on prognosis of Asian patients with mCRPC.
| Item Type: | Article |
|---|---|
| Funders: | Sanofi, Ministry of Health Singapore NMRC-IAF grant |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 15 Jan 2025 07:46 |
| Last Modified: | 15 Jan 2025 07:46 |
| URI: | http://eprints.um.edu.my/id/eprint/46911 |
Actions (login required)
 |
View Item |
